Demographics and comorbidities of patients with AAV at diagnosis.
| Cases, n | All AAV 195 | ANCA– 28 | MPO 143 | PR3 19 | P, All | P, MPO vs ANCA– | P, MPO vs PR3 |
|---|---|---|---|---|---|---|---|
| Sex, female | 57.6 | 50.0 | 58.7 | 63.2 | > 0.1 | > 0.1 | > 0.1 |
| Age, yrs, mean ± SD | 69.2 ±12.2 | 58.4 ± 14.2 | 71.4 ± 10.7 | 69.7 ± 10.7 | < 0.0001 | 0.0002 | > 0.1 |
| Pathological proof of vasculitis | 33.3 | 57.1 | 30.8 | 21.1 | 0.02 | 0.045 | > 0.1 |
| EGPAa | 12.3 (33.3) | 46.4 (30.0) | 7.0 (30.0) | 5.3 (0.0) | < 0.0001 | < 0.0001 | > 0.1 |
| GPAa | 26.2 (31.4) | 21.4 (100) | 18.9 (22.2) | 79.0 (20.0) | < 0.0001 | > 0.1 | < 0.0001 |
| MPAa | 45.6 (46.1) | 21.4 (83.3) | 56.6 (43.2) | 10.5 (50.0) | < 0.0001 | 0.0003 | < 0.0001 |
| uAAVa | 15.9 (0.0) | 17.5 (0.0) | 17.5 (0.0) | 5.3 (0.0) | > 0.1 | > 0.1 | 0.10 |
| Smoking | 35.7 | 32.2 | 32.2 | 36.8 | > 0.1 | > 0.1 | > 0.1 |
| Comorbidity | 88.2 | 96.4 | 87.4 | 78.9 | > 0.1 | > 0.1 | > 0.1 |
| n, mean ± SD | 1.9 ± 1.4 | 1.6 ± 1.0 | 2.0 ± 1.5 | 1.7 ± 1.3 | > 0.1 | > 0.1 | > 0.1 |
| Airway comorbidity | 68.7 | 75.0 | 70.6 | 47.4 | > 0.1 | > 0.1 | 0.049 |
| n, mean ± SD | 1.1 ± 1.0 | 1.1 ± 0.8 | 1.2 ± 1.1 | 0.7 ± 1.0 | > 0.1 | > 0.1 | 0.04 |
| Allergic airway | 15.3 | 50.0 | 9.8 | 10.5 | < 0.0001 | < 0.0001 | > 0.1 |
| Upper airway | 13.8 | 10.7 | 13.3 | 26.3 | > 0.1 | > 0.1 | > 0.1 |
| Bronchiectasis | 15.4 | 10.7 | 18.8 | 0 | 0.02 | > 0.1 | 0.008 |
| Pulmonary infections | 7.7 | 7.1 | 7.0 | 10.5 | > 0.1 | > 0.1 | > 0.1 |
| Emphysema | 1.8 | 7.1 | 21.0 | 10.5 | > 0.1 | > 0.1 | > 0.1 |
| fILD | 34.3 | 7.1 | 44.1 | 10.5 | < 0.0001 | 0.0002 | 0.002 |
| Heart disease | 8.2 | 7.1 | 6.3 | 21.0 | > 0.1 | > 0.1 | 0.05 |
| Atherosclerotic disease | 43.1 | 17.9 | 46.8 | 42.1 | 0.01 | 0.01 | > 0.1 |
| Malignancy | 9.7 | 3.6 | 11.1 | 10.5 | > 0.1 | > 0.1 | > 0.1 |
| Use of CYC, 6m | 34.7 | 33.3 | 35.2 | 26.3 | > 0.1 | > 0.1 | > 0.1 |
| Use of RTX, 6m | 11.9 | 3.7 | 12.7 | 21.1 | > 0.1 | > 0.1 | > 0.1 |
Values are presented as % unless otherwise stated. Values in bold are significant.
↵a The ratio of patients with pathological proof of vasculitis. AAV: ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibody; CYC: cyclophosphamide; EGPA: eosinophilic granulomatosis with polyangiitis; fILD: fibrotic interstitial lung disease; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; MPO: myeloperoxidase; PR3: proteinase 3; RTX: rituximab; uAAV: unclassified AAV.